Adaptive Biotechnologies (ADPT) to Release Earnings on Tuesday

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) is scheduled to be releasing its earnings data on Tuesday, April 2nd.

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. The company had revenue of $45.78 million during the quarter, compared to the consensus estimate of $50.15 million. Adaptive Biotechnologies had a negative net margin of 132.29% and a negative return on equity of 53.65%. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Trading Up 11.1 %

ADPT stock opened at $3.21 on Monday. The company has a market cap of $465.74 million, a price-to-earnings ratio of -2.06 and a beta of 1.27. Adaptive Biotechnologies has a 12 month low of $2.61 and a 12 month high of $9.08. The firm has a 50-day moving average of $3.70 and a two-hundred day moving average of $4.33.

Insider Transactions at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 48,673 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total transaction of $166,948.39. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares of the company’s stock, valued at approximately $8,838,084.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 48,673 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total value of $166,948.39. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares of the company’s stock, valued at approximately $8,838,084.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Tycho Peterson sold 15,456 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $3.44, for a total transaction of $53,168.64. Following the completion of the transaction, the chief financial officer now directly owns 531,553 shares of the company’s stock, valued at approximately $1,828,542.32. The disclosure for this sale can be found here. Insiders sold 124,307 shares of company stock worth $428,090 in the last 90 days. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Adaptive Biotechnologies by 4.2% during the 4th quarter. Vanguard Group Inc. now owns 12,767,684 shares of the company’s stock worth $62,562,000 after purchasing an additional 518,642 shares during the last quarter. BlackRock Inc. raised its stake in Adaptive Biotechnologies by 12.2% during the 3rd quarter. BlackRock Inc. now owns 10,119,409 shares of the company’s stock worth $72,051,000 after acquiring an additional 1,098,301 shares in the last quarter. Bellevue Group AG raised its stake in Adaptive Biotechnologies by 59.8% during the 1st quarter. Bellevue Group AG now owns 3,145,293 shares of the company’s stock worth $43,657,000 after acquiring an additional 1,176,862 shares in the last quarter. State Street Corp raised its stake in Adaptive Biotechnologies by 2.7% during the 1st quarter. State Street Corp now owns 2,568,042 shares of the company’s stock worth $22,672,000 after acquiring an additional 66,589 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Adaptive Biotechnologies by 3.2% during the 2nd quarter. Geode Capital Management LLC now owns 2,286,626 shares of the company’s stock worth $15,343,000 after acquiring an additional 70,646 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. The Goldman Sachs Group cut their price objective on shares of Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, February 16th. JPMorgan Chase & Co. cut their price objective on shares of Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating for the company in a report on Thursday, February 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $7.25.

Read Our Latest Research Report on ADPT

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Featured Articles

Earnings History for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.